Anthem Health Plans Play Major Role in Trial to Determine Best Aspirin Dose to Prevent Heart Attacks and Strokes

INDIANAPOLIS–()–Anthem Inc. is committed to playing an active role in identifying best
approaches to health and care management. As part of that belief,
Anthem’s outcomes research subsidiary, HealthCore Inc., will begin
reaching out to select members of Anthem affiliated health plans
regarding an opportunity to participate in an innovative research study
on heart disease. The study is currently underway to help determine the
most effective and safest dose of aspirin to prevent heart attacks and
strokes, and Anthem’s affiliated health plans are expected to play a
significant role in recruitment.

This landmark study, called ADAPTABLE, involves more than 30 leading
health and medical organizations across the U.S. with a goal of
enrolling 15,000 participants. The study, which is funded by the
Patient-Centered Outcomes Research Institute (PCORI), will compare
regular strength aspirin (325mg) to “baby” aspirin (81mg) among people
with heart disease to help determine the best dose to use. While aspirin
is widely prescribed to prevent strokes and heart attacks in people
living with heart disease, the right dose is not established. This is
because one dose may be better at preventing heart attacks while another
may prevent serious side effects, such as bleeding.

Heart disease causes one in four deaths in the U.S., making it the
country’s leading killer, and heart disease places enormous burdens on
patients and their families as well as the U.S. healthcare system. While
the ADAPTABLE trial is important on its own, it’s also the first study
to be conducted through PCORnet, the National Patient-Centered Clinical
Research Network. This innovative PCORI initiative is designed to
empower people to make informed healthcare decisions by enabling

Article Source…

Leave a Reply

Your email address will not be published. Required fields are marked *